Fenwick Represents Merck Global Health Innovation Fund and Strategic Investor Consortium in Investment in Saama

Fenwick represented long-standing client Merck Global Health Innovation Fund and a consortium of strategic and financial healthcare-focused investors, including Amgen Ventures, Intermountain Health Ventures, McKesson Ventures, Northpond Ventures, Pfizer Ventures and Population Health Partners, in a strategic growth financing transaction led by The Carlyle Group into Saama Technologies. The round will raise up to $430 million for Saama and will allow Saama, an AI-driven clinical cloud company, to accelerate its strategic initiatives. More information can be obtained from Saama's announcement.

The Fenwick transaction team was led by corporate partner Ian Goldstein and included corporate associates Ryan McRobert and Óisín O’Callaghan and tax associate Michael Knobler.